Amgen (AMGN) EPS (Basic) Growth (1y) (2010 - 2026)
Powered by 
Analysis
Amgen (AMGN) EPS (Basic) Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.59 Bn | 193.60 Bn | 7.24 Bn | 65.24% |
| 2 | Gilead Sciences | 178.73 Bn | 175.55 Bn | 6.22 Bn | -636.10% |
| 3 | Vertex Pharmaceuticals | 131.17 Bn | 123.32 Bn | 2.84 Bn | 7.74% |
| 4 | Regeneron Pharmaceuticals | 81.73 Bn | 73.73 Bn | 3.93 Bn | -4.72% |
| 5 | Argenx Se | 61.01 Bn | 55.82 Bn | 1.37 Bn | 87.85% |
| 6 | Moderna | 53.40 Bn | 48.27 Bn | 52.00 Mn | 7.59% |
| 7 | Alnylam Pharmaceuticals | 33.49 Bn | 30.18 Bn | 992.69 Mn | 322.67% |
| 8 | Biogen | 31.64 Bn | 30.35 Bn | 1.96 Bn | -84.77% |
| 9 | Roivant Sciences | 29.66 Bn | 29.66 Bn | 1.16 Mn | - |
| 10 | Insmed | 27.74 Bn | 26.58 Bn | 358.27 Mn | 96.41% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 65.24% |
| Mar 31, 2026 | 4.76% |
| Dec 31, 2025 | 112.20% |
| Sep 30, 2025 | 13.43% |
| Jun 30, 2025 | 91.60% |
| Mar 31, 2025 | 1,625.28% |
| Dec 31, 2024 | -18.56% |
| Sep 30, 2024 | 62.97% |
| Jun 30, 2024 | -46.10% |
| Mar 31, 2024 | -103.96% |
| Dec 31, 2023 | -52.27% |
| Sep 30, 2023 | -19.27% |
| Jun 30, 2023 | 4.71% |
| Mar 31, 2023 | 97.53% |
| Dec 31, 2022 | -9.84% |
| Sep 30, 2022 | 20.55% |
| Jun 30, 2022 | 204.00% |
| Mar 31, 2022 | -5.58% |
| Dec 31, 2021 | 20.89% |
| Sep 30, 2021 | -3.82% |